Welcome to our dedicated page for 10X Genomics news (Ticker: TXG), a resource for investors and traders seeking the latest updates and insights on 10X Genomics stock.
10x Genomics, Inc. (Nasdaq: TXG) is a leading life science technology company based in Pleasanton, California. The company specializes in creating innovative solutions for single cell and spatial biology research, providing researchers with the tools necessary to advance human health by deepening the understanding of complex biological systems.
10x Genomics' product portfolio includes cutting-edge instruments, consumables, and software designed for high-resolution, large-scale analysis of biological systems. Among its notable products are the Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software. The bulk of the company's revenue is generated from the sale of consumables, which are crucial for ongoing research and experimental workflows.
Recently, 10x Genomics launched the GEM-X technology, a significant upgrade to its existing single cell technology. The GEM-X platform offers enhanced performance and reliability, enabling more comprehensive single cell analysis. The company has also introduced the Xenium product line, including the Xenium multi-modal cell segmentation kit and an immuno-oncology gene panel, which expands their single cell spatial analysis capabilities.
Financially, 10x Genomics has demonstrated growth, with 2023 revenue reaching $618.7 million, an increase from the previous year. Although the company reported a net loss for the same period, the launch of new products like the Visium HD Spatial Gene Expression assay and the continued development of the GEM-X technology are expected to drive future growth and adoption among researchers worldwide.
10x Genomics collaborates closely with academic and translational researchers, as well as biopharmaceutical companies, to fuel discoveries in fields such as oncology, immunology, and neuroscience. Their integrated solutions enable scientists to study biological systems at a resolution and scale that aligns with the complexity of biology, making significant contributions to the understanding of health and disease.
To stay up-to-date with 10x Genomics' latest developments, visit their official website at 10xgenomics.com, or follow them on LinkedIn and X (Twitter).
10x Genomics (TXG) has announced that it will release its financial results for Q4 and full year ended December 31, 2020, after the market close on February 17, 2021. A conference call to discuss the results and company outlook will begin at 1:30 PM PT. The event will be accessible via webcast on the company's website and archived for replay for 45 days. 10x Genomics focuses on life science technology, providing solutions that enhance biological understanding, serving major global research institutions and pharmaceutical companies.
10x Genomics (Nasdaq: TXG) will participate in the 39th Annual J.P. Morgan Virtual Healthcare Conference, scheduled for January 11, 2021, at 7:00 a.m. PT / 10:00 a.m. ET. The company's management will present key information, and interested parties can access a live and archived webcast on their Investors page.
10x Genomics develops integrated solutions for biological research, with products widely adopted by leading research institutions and pharmaceutical companies.
10x Genomics, Inc. (TXG) reported Q3 2020 revenue of $71.8 million, a 17% increase year-over-year and a 67% increase from Q2 2020. The company made significant acquisitions of ReadCoor and CartaNA, enhancing its capabilities in In Situ analysis. Despite revenue growth, operating expenses surged 124% to $122.7 million, leading to an operating loss of $65.3 million and a net loss of $65.8 million. The company has withdrawn its full-year revenue guidance due to ongoing COVID-19 uncertainties.
10x Genomics (Nasdaq: TXG) will participate in the Stifel Virtual Healthcare Conference on November 16 at 11:40 a.m. PT. The presentation will be accessible via a live and archived webcast on the company’s investors page.
10x Genomics offers advanced products for biological analysis, utilized by 97 of the top 100 research institutions and 19 of the top 20 pharmaceutical companies. With over 1,750 citations in research, the company holds a patent portfolio of more than 825 patents and applications.
10x Genomics (TXG) will report its third-quarter financial results on November 10, 2020, post-market. A conference call will follow at 2:00 PM PT to discuss outcomes, business developments, and future outlook.
The event will be available for live audio streaming on the company’s website, with a recording accessible for 45 days thereafter. 10x Genomics specializes in life science technologies, offering comprehensive solutions for biological analysis, widely adopted by leading research institutions and pharmaceutical companies.
10x Genomics (Nasdaq: TXG) announced a definitive agreement to acquire ReadCoor, a developer of In Situ technologies, for $350 million in cash and stock. This follows the acquisition of CartaNA AB, enhancing 10x's capabilities in In Situ RNA analysis. Together, these acquisitions are expected to develop comprehensive intellectual property and technology in the emerging In Situ field, potentially establishing a new technology platform and broadening customer applications. The ReadCoor acquisition is anticipated to complete later this month, subject to shareholder approval.
10x Genomics, Inc. (NASDAQ: TXG) announced the successful closing of a public offering for 4,600,000 shares of its Class A common stock, including the full exercise of an underwriters’ option for an additional 600,000 shares. Priced at $110.00 per share, the total gross proceeds amounted to $506 million prior to underwriting discounts and expenses. J.P. Morgan Securities LLC, BofA Securities, and Cowen and Company acted as lead managers. Registration statements for this offering were effective as of September 10, 2020.
10x Genomics (Nasdaq: TXG) has announced the commercial shipping of its Chromium Single Cell Multiome ATAC + Gene Expression solution, the first product to simultaneously profile a cell's epigenome and transcriptome. This innovative approach enhances research capabilities by directly linking epigenetic programs to gene expression, improving understanding of cell functionality and disease mechanisms. Early adopters include Stanford and Mt. Sinai, emphasizing its potential in studying immune response to cancer and neuropsychiatric diseases.
10x Genomics, Inc. (NASDAQ: TXG) announced a public offering of 4,000,000 shares of its Class A common stock, priced at $110.00 each. An additional 600,000 shares may be purchased by underwriters. The offering is expected to close on September 15, 2020, pending customary closing conditions. The underwriting group consists of J.P. Morgan Securities LLC, BofA Securities, and Cowen and Company, with Stifel and William Blair as co-managers. This offering aims to strengthen the company's capital position.
10x Genomics (NASDAQ: TXG) announced a public offering of 3,500,000 shares of its Class A common stock. The offering is underwritten by J.P. Morgan, BofA Securities, and Cowen and Company, with a 30-day option for underwriters to purchase an additional 525,000 shares. A preliminary registration statement has been filed with the SEC but is not yet effective, meaning shares cannot be sold until it is approved. The company aims to raise capital for ongoing business operations.
FAQ
What is the current stock price of 10X Genomics (TXG)?
What is the market cap of 10X Genomics (TXG)?
What does 10x Genomics, Inc. specialize in?
What are some of the key products of 10x Genomics?
What recent technological advancements has 10x Genomics introduced?
How has 10x Genomics performed financially in recent years?
Who are the primary users of 10x Genomics' products?
What is the significance of GEM-X technology?
Where can I find the latest news about 10x Genomics?
What is the focus of 10x Genomics' recent product launches?
What is the impact of 10x Genomics' products on scientific research?
How does 10x Genomics contribute to the field of biology?
